FTH Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. (FTH) is expected to report earnings on November 3, 2026. The consensus earnings estimate is a loss of $0.66 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +26.2% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Faeth Therapeutics, Inc.
Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company's product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md.
Sector
Healthcare
Industry
Biotechnology